![](/fileadmin/_processed_/csm_Ohr_01cd9c4461.jpg)
Sensorion achieves milestones in Phase II trial
Following cochlear implantation, SENS-401, a 5HT3R antagonist that blocks the CalN pathway, reduced sudden hearing loss as measured by the...
![](/fileadmin/Content/NewsAndStories/2024/Enk_freitag.png)
Friday: CRISPR screen highlights genes behind T cell plasticity in autoimmunity
Pro-inflammatory CD4-positive T cells are major drivers of autoimmune diseases, yet therapiesmodulating T cell phenotypes to promote an...
![](/fileadmin/_processed_/csm_Ipsen_headquarters.__c__Ipsen_SA_865320fa5c.jpg)
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
![](/fileadmin/_processed_/csm_valneva_lab-web-STA_3217-scaled_e65f26fc69.jpg)
Valneva gets approval for Chikungunya vaccine in Canada
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today that Health Canada has approved IXCHIQ®, Valneva's single-dose vaccine for the...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_SFactory01_Launch_044ec847f4.png)
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
![](/fileadmin/_processed_/csm_Fundus_of_patient_with_retinitis_pigmentosa__mid_stage_10790b28cb.jpg)
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...